創傷治療用生物製剤市場：製品別（生体皮膚代替物、外用剤）、創傷タイプ別（潰瘍［糖尿病性足、静脈、褥瘡］、手術創・外傷、熱傷）、エンドユーザー別（病院、ASC、熱傷センター）-2027年までの世界市場予測

Wound Care Biologics Market by Product (Biological Skin Substitutes, Topical Agents), Wound Type (Ulcers [Diabetic Foot, Venous, Pressure Ulcers], Surgical & Traumatic Wounds, Burns), End User (Hospitals, ASCs, Burn Centers) – Global Forecast to 2027

創傷治療用生物製剤の世界市場は、2022年に推定18億米ドルと評価され、予測期間中にCAGR5.4％で2027年には24億米ドルに達すると予測されています。市場成長の背景には、火傷の発生率の増加や交通事故の増加、それ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年6月14日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	174	214	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

創傷治療用生物製剤の世界市場は、2022年に推定18億米ドルと評価され、予測期間中にCAGR5.4％で2027年には24億米ドルに達すると予測されています。市場成長の背景には、火傷の発生率の増加や交通事故の増加、それに伴う外傷の増加といった要因があります。しかし、創傷治療用生物学的製剤のコストが高いことや、皮膚代替物の不具合に伴うリスクが、この市場の成長を阻害する主な要因となっています。

"予測期間中の製品別では、生物学的皮膚代替物が創傷ケア生物学的製剤市場で最も高い成長率を占めた"
創傷治療用生物製剤市場は、生物学的皮膚代用剤と外用剤に区分されます。生物学的皮膚代替物は、予測期間中に最も高い成長率を記録すると予想されます。外科的・外傷的創傷の負担増加や熱傷の増加などの要因が、このセグメントの成長に寄与しています。
「病院向けが最も高いCAGRを記録
エンドユーザーに基づいて、創傷ケア生物製剤市場は、病院、外来手術センター、火傷ケアセンター＆創傷クリニックに区分されます。病院セグメントは、予測期間中に最も高いCAGRを記録すると予想されます。慢性疾患を持つ患者の長期入院や再入院により、さまざまな創傷治療用生物製剤の採用が増加しています。院内創傷の発生率の増加は、この市場セグメントの主要な成長要因です。また、病院は購買力が高く、高度な技術を持つ医療従事者がおり、技術的に発展した手術施設を利用できるため、創傷治療用生物学的製剤の採用が進んでいます。
"アジア太平洋地域は、予測期間中に最も高いCAGRで成長すると予想される"
世界の創傷治療用生物製剤市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカの5地域に区分されます。アジア太平洋地域は、予測期間中、創傷治療用生物製剤市場で最も高い成長を遂げると予想されています。この地域の高成長は、主に糖尿病の有病率の増加、医療支出の増加、一人当たりの所得の増加、APAC諸国の地方への民間病院の拡大、医療観光の増加、高成長市場の存在に起因しています。この地域の低い労働コストと良好な規制環境も市場成長の推進要因になると予想されます。

本レポートのために実施した主なインタビューは、以下のように分類されます。

- 企業タイプ別企業タイプ別：Tier 1 - 40%, Tier 2 - 30%, Tier 3 -30
- 役職別Cレベル：27％、Dレベル：18％、その他：55
- 地域別北米：51%、欧州：21%、アジア太平洋：18%、中南米：6%、中東・アフリカ：4
レポート掲載企業リスト

- スミス・アンド・ネフュー plc（英国）
- オルガノジェネシス社（米国）
- MIMEDX（米国）
- インテグラライフサイエンス（米）
- ストライカー社（米国）
- メルンリッケ・ヘルスケアAB（スウェーデン）
- ベリセル・コーポレーション（米国）
- バイオベンタス社（米国）
- アニカセラピューティック社（米国）
- アッヴィー社（米国）
- ケレシス社（アイスランド）
- マリンポリマーテクノロジーズ社（米国）
- メラクリス・セラピューティクス（米国）
- PolyMedics Innovations GmbH（ドイツ）
- FibrohealWoundcarePvt.Ltd.(インド)(インド)
- Anamay Biotech, Inc.(インド)
- Virchow Biotech Private Limited（インド）
- Medline Industries, LP（米国）
- タイズメディカル（米国）
- ビスカスバイオロジクス社（米国）
- スタビリティ・バイオロジクス（米国）
- MTF Biologics（米国）
- スカイバイオロジックス・ホールディングス LLC（米国）
- AlloSource社（米国）
- サージロジックス社（米国）

調査対象
本レポートは、世界の創傷治療用生物製剤市場の詳細図を提供します。製品、創傷タイプ、エンドユーザー、地域など、さまざまなセグメントにおける市場規模と今後の成長可能性を推定することを目的としています。また、市場主要企業の詳細な競合分析、企業プロファイル、最近の開発状況、主要な市場戦略も掲載しています。

レポートを購入する主な利点。
本レポートは、創傷治療用生物製剤市場全体とそのサブセグメントに関する収益数の最も近い概算を提供することで、市場リーダーや新規参入者に役立ちます。また、利害関係者が競争環境をよりよく理解し、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会に関する情報を提供することを可能にします。

ページTOPに戻る

1 INTRODUCTION 27
1.1 OBJECTIVES OF THE STUDY 27
1.2 MARKET DEFINITION 27
1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY 28
1.2.2 MARKETS COVERED 28
FIGURE 1 WOUND CARE BIOLOGICS MARKET 28
1.2.3 YEARS CONSIDERED FOR THE STUDY 29
1.3 CURRENCY 29
1.4 LIMITATIONS 29
1.5 STAKEHOLDERS 30
1.6 SUMMARY OF CHANGES 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
2.2 RESEARCH APPROACH 31
FIGURE 2 WOUND CARE BIOLOGICS MARKET: RESEARCH DESIGN METHODOLOGY 31
2.2.1 SECONDARY DATA 32
2.2.1.1 Key data from secondary sources 32
2.2.2 PRIMARY DATA 33
2.2.2.1 Primary sources 33
2.2.2.2 Key data from primary sources 34
2.2.2.3 Key industry insights 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.3 MARKET SIZE ESTIMATION 36
2.3.1 BOTTOM-UP APPROACH 36
2.3.1.1 Approach 1: Company revenue estimation approach 36
FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH 36
2.3.1.2 Approach 3: Presentations of companies and primary interviews 37
2.3.1.3 Growth forecast 37
2.3.1.4 CAGR projections 37
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 37
2.3.2 TOP-DOWN APPROACH 38
FIGURE 6 WOUND CARE BIOLOGICS MARKET: TOP-DOWN APPROACH 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39
FIGURE 7 DATA TRIANGULATION METHODOLOGY 39
2.5 MARKET SHARE 40
2.6 ASSUMPTIONS FOR THE STUDY 40
3 EXECUTIVE SUMMARY 41
FIGURE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2022 VS. 2027 (USD MILLION) 41
FIGURE 9 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2022 VS. 2027 (USD MILLION) 42
FIGURE 10 WOUND CARE BIOLOGICS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 42
FIGURE 11 WOUND CARE BIOLOGICS MARKET, BY REGION,
2022 VS. 2027 (USD MILLION) 43
4 PREMIUM INSIGHTS 44
4.1 WOUND CARE BIOLOGICS MARKET OVERVIEW 44
FIGURE 12 INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET FOR WOUND CARE BIOLOGICS 44
4.2 WOUND CARE BIOLOGICS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 44
FIGURE 13 BIOLOGICAL SKIN SUBSTITUTES WILL CONTINUE TO DOMINATE MARKET IN 2027 44
4.3 WOUND CARE BIOLOGICS MARKET SHARE, BY WOUND TYPE, 2022 VS. 2027 45
FIGURE 14 ULCERS SEGMENT DOMINATES MARKET 45
4.4 WOUND CARE BIOLOGICS MARKET SHARE, BY END USER, 2022 VS. 2027 45
FIGURE 15 HOSPITALS ARE LARGEST END USERS OF WOUND CARE BIOLOGICS 45
4.5 WOUND CARE BIOLOGICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 46
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN WOUND CARE BIOLOGICS MARKET DURING FORECAST PERIOD 46
5 MARKET OVERVIEW 47
5.1 INTRODUCTION 47
5.2 MARKET DYNAMICS 47
FIGURE 17 WOUND CARE BIOLOGICS MARKET: DRIVERS, RESTRAINTS, AND OPPORTUNITIES 47
5.2.1 DRIVERS 47
5.2.1.1 Growing prevalence of diseases & conditions affecting wound healing capabilities 47
5.2.1.1.1 Growing geriatric population 48
5.2.1.1.2 Increasing prevalence of diabetes and target conditions 48
FIGURE 18 PREVALENCE OF DIABETES IN ADULTS (20–79 YEARS), BY REGION,
2021 VS. 2045 (MILLION CASES) 49
TABLE 1 TOTAL HEALTH EXPENDITURE (USD) DUE TO DIABETES (20–79 YEARS) IN 2021, BY COUNTRY 49
TABLE 2 LIST OF COMMERCIALLY AVAILABLE SKIN SUBSTITUTES, THEIR INDICATIONS, AND SUPPORTING EVIDENCE FOR USE IN CHRONIC WOUNDS 50
5.2.1.1.3 Increasing number of surgical procedures across the globe 50
5.2.1.1.4 Increasing number of traumatic wounds 51
TABLE 3 PREVALENCE OF ROAD ACCIDENTS 51
5.2.1.2 Increasing incidence of burn injuries 51
5.2.1.3 Innovations in wound care biologics 52
5.2.2 MARKET RESTRAINTS 52
5.2.2.1 High cost of wound care biologic products 52
TABLE 4 AVERAGE COST OF TREATMENT FOR DIABETIC FOOT ULCERS (2018) 52
5.2.2.2 Risk of skin substitute failure 53
TABLE 5 COMPARISON OF OUTCOMES (STSG VS. FTSG PATIENTS) 53
5.2.3 OPPORTUNITIES 54
5.2.3.1 Growth potential of emerging economies 54
TABLE 6 STRATEGIC DEVELOPMENTS IN THE ASIA PACIFIC 54
5.2.3.2 3D skin printing 55
5.3 IMPACT OF COVID-19 ON THE WOUND CARE BIOLOGICS MARKET 55
6 WOUND CARE BIOLOGICS MARKET, BY PRODUCT 57
6.1 INTRODUCTION 58
TABLE 7 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 58
TABLE 8 WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 58
6.2 BIOLOGICAL SKIN SUBSTITUTES 58
TABLE 9 KEY PRODUCTS IN THE BIOLOGICAL SKIN SUBSTITUTES MARKET 59
TABLE 10 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2017–2020 (USD MILLION) 59
TABLE 11 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY REGION, 2021–2027 (USD MILLION) 60
TABLE 12 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2017–2020 (USD MILLION) 60
TABLE 13 WOUND CARE BIOLOGICS MARKET FOR BIOLOGICAL SKIN SUBSTITUTES, BY TYPE, 2021–2027 (USD MILLION) 60
6.2.1 HUMAN DONOR TISSUE-DERIVED PRODUCTS 61
6.2.1.1 High efficacy of human donor tissue-derived products to support market demand 61
TABLE 14 KEY PRODUCTS IN THE HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET 61
TABLE 15 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION) 62
TABLE 16 HUMAN DONOR TISSUE-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION) 62
6.2.2 ACELLULAR ANIMAL-DERIVED PRODUCTS 62
6.2.2.1 Recognition of the importance of ECM in wound treatment has led to the development of acellular wound care biologics 62
TABLE 17 KEY PRODUCTS IN THE ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET 63
TABLE 18 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2017–2020 (USD MILLION) 63
TABLE 19 ACELLULAR ANIMAL-DERIVED PRODUCTS MARKET, BY REGION,
2021–2027 (USD MILLION) 64
6.2.3 BIOSYNTHETIC PRODUCTS 64
6.2.3.1 Increased bioburden of infected wounds to stimulate market growth 64
TABLE 20 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2017–2020 (USD MILLION) 64
TABLE 21 BIOSYNTHETIC PRODUCTS MARKET, BY REGION, 2021–2027 (USD MILLION) 65
6.3 TOPICAL AGENTS 65
6.3.1 INCREASE IN THE NUMBER OF CHRONIC ULCERS OVER THE LAST FEW YEARS TO PROPEL MARKET GROWTH 65
TABLE 22 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2017–2020 (USD MILLION) 66
TABLE 23 WOUND CARE BIOLOGICS MARKET FOR TOPICAL AGENTS, BY REGION, 2021–2027 (USD MILLION) 66
7 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE 67
7.1 INTRODUCTION 68
TABLE 24 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 68
TABLE 25 WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 68
7.1.1 PRIMARY NOTES 68
7.1.1.1 Key industry insights 68
7.2 ULCERS 69
TABLE 26 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2017–2020 (USD MILLION) 69
TABLE 27 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY REGION,
2021–2027 (USD MILLION) 70
TABLE 28 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2017–2020 (USD MILLION) 70
TABLE 29 WOUND CARE BIOLOGICS MARKET FOR ULCERS, BY TYPE,
2021–2027 (USD MILLION) 70
7.2.1 DIABETIC FOOT ULCERS 71
7.2.1.1 Increasing prevalence of diabetes to drive market growth 71
TABLE 30 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2017–2020 (USD MILLION) 71
TABLE 31 WOUND CARE BIOLOGICS MARKET FOR DIABETIC FOOT ULCERS, BY REGION, 2021–2027 (USD MILLION) 72
7.2.2 VENOUS ULCERS 72
7.2.2.1 Rising prevalence of obesity to drive market growth 72
TABLE 32 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2017–2020 (USD MILLION) 73
TABLE 33 WOUND CARE BIOLOGICS MARKET FOR VENOUS ULCERS, BY REGION, 2021–2027 (USD MILLION) 73
7.2.3 PRESSURE ULCERS 73
7.2.3.1 Growing geriatric population to drive market growth 73
TABLE 34 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2017–2020 (USD MILLION) 74
TABLE 35 WOUND CARE BIOLOGICS MARKET FOR PRESSURE ULCERS, BY REGION, 2021–2027 (USD MILLION) 74
7.2.4 OTHER ULCERS 75
TABLE 36 COMMERCIALLY AVAILABLE WOUND CARE BIOLOGIC PRODUCTS FOR OTHER ULCERS 75
TABLE 37 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2017–2020 (USD MILLION) 75
TABLE 38 WOUND CARE BIOLOGICS MARKET FOR OTHER ULCERS, BY REGION,
2021–2027 (USD MILLION) 76
7.3 SURGICAL & TRAUMATIC WOUNDS 76
7.3.1 RISING VOLUME OF SURGICAL PROCEDURES TO DRIVE MARKET GROWTH 76
TABLE 39 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2017–2020 (USD MILLION) 77
TABLE 40 WOUND CARE BIOLOGICS MARKET FOR SURGICAL & TRAUMATIC WOUNDS, BY REGION, 2021–2027 (USD MILLION) 77
7.4 BURNS 77
7.4.1 HIGH INCIDENCE OF BURN INJURIES IN EMERGING COUNTRIES TO DRIVE MARKET GROWTH 77
TABLE 41 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2017–2020 (USD MILLION) 78
TABLE 42 WOUND CARE BIOLOGICS MARKET FOR BURNS, BY REGION,
2021–2027 (USD MILLION) 79
8 WOUND CARE BIOLOGICS MARKET, BY END USER 80
8.1 INTRODUCTION 81
TABLE 43 WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 81
TABLE 44 WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 81
8.2 HOSPITALS 81
8.2.1 INCREASING NUMBER OF HOSPITALS & HIGH PATIENT INFLOW IN THIS CARE SETTING TO SUPPORT MARKET GROWTH 81
TABLE 45 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2017–2020 (USD MILLION) 83
TABLE 46 WOUND CARE BIOLOGICS MARKET FOR HOSPITALS, BY REGION,
2021–2027 (USD MILLION) 83
8.3 AMBULATORY SURGERY CENTERS 83
8.3.1 GROWING NUMBER OF SURGICAL PROCEDURES PERFORMED IN ASCS WILL ENSURE MARKET GROWTH IN THIS SEGMENT 83
TABLE 47 NUMBER OF BURN PATIENTS PER 1,000 ASC ADMISSIONS 84
TABLE 48 PRICE ASSESSMENT OF WOUND CARE BIOLOGICS IN AMBULATORY SURGERY CENTERS IN THE US 84
TABLE 49 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2017–2020 (USD MILLION) 84
TABLE 50 WOUND CARE BIOLOGICS MARKET FOR AMBULATORY SURGERY CENTERS, BY REGION, 2021–2027 (USD MILLION) 85
8.4 BURN CARE CENTERS & WOUND CLINICS 85
8.4.1 RISING GERIATRIC POPULATION AND THE SUBSEQUENT INCREASE IN THE DEMAND FOR ASSISTED LIVING FACILITIES TO SUPPORT MARKET GROWTH 85
TABLE 51 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2017–2020 (USD MILLION) 86
TABLE 52 WOUND CARE BIOLOGICS MARKET FOR BURN CARE CENTERS & WOUND CLINICS, BY REGION, 2021–2027 (USD MILLION) 86
9 WOUND CARE BIOLOGICS MARKET, BY REGION 87
9.1 INTRODUCTION 88
TABLE 53 WOUND CARE BIOLOGICS MARKET, BY REGION, 2017–2020 (USD MILLION) 88
TABLE 54 WOUND CARE BIOLOGICS MARKET, BY REGION, 2021–2027 (USD MILLION) 88
9.2 NORTH AMERICA 89
FIGURE 19 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET SNAPSHOT 90
TABLE 55 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 90
TABLE 56 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 91
TABLE 57 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 91
TABLE 58 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 91
TABLE 59 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION) 92
TABLE 60 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION) 92
TABLE 61 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 92
TABLE 62 NORTH AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 93
9.2.1 US 93
9.2.1.1 Increasing prevalence of diabetes and non-healing foot ulcers to support the uptake of wound biologics products 93
TABLE 63 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 94
TABLE 64 US: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 94
TABLE 65 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 94
TABLE 66 US: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 95
TABLE 67 US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 95
TABLE 68 US: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 95
9.2.2 CANADA 96
9.2.2.1 Rising geriatric patient pool to drive market growth for wound biologics in Canada 96
TABLE 69 INCIDENCE OF DIABETES IN CANADA, 2019 VS. 2029 96
TABLE 70 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 97
TABLE 71 CANADA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 97
TABLE 72 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 97
TABLE 73 CANADA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 98
TABLE 74 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 98
TABLE 75 CANADA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 98
9.3 EUROPE 99
TABLE 76 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 99
TABLE 77 EUROPE: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 100
TABLE 78 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 100
TABLE 79 EUROPE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 100
TABLE 80 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 101
TABLE 81 EUROPE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 101
TABLE 82 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 101
TABLE 83 EUROPE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 102
9.3.1 UK 102
9.3.1.1 Increasing incidence of venous ulcers to drive the market growth 102
TABLE 84 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 102
TABLE 85 UK: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 103
TABLE 86 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 103
TABLE 87 UK: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 103
TABLE 88 UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 104
TABLE 89 UK: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 104
9.3.2 GERMANY 104
9.3.2.1 The large diabetic population in Germany supports the uptake of wound biologics in Germany 104
TABLE 90 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 105
TABLE 91 GERMANY: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 105
TABLE 92 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 105
TABLE 93 GERMANY: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 106
TABLE 94 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 106
TABLE 95 GERMANY: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 106
9.3.3 FRANCE 107
9.3.3.1 Rising government support to drive the demand for wound care biologics products in France 107
TABLE 96 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 107
TABLE 97 FRANCE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 107
TABLE 98 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 108
TABLE 99 FRANCE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 108
TABLE 100 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 108
TABLE 101 FRANCE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 109
9.3.4 REST OF EUROPE 109
TABLE 102 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 110
TABLE 103 ROE: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 110
TABLE 104 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 110
TABLE 105 ROE: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 111
TABLE 106 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 111
TABLE 107 ROE: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 111
9.4 ASIA PACIFIC 112
FIGURE 20 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET SNAPSHOT 112
TABLE 108 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2017–2020 (USD MILLION) 113
TABLE 109 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY COUNTRY,
2021–2027 (USD MILLION) 113
TABLE 110 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 113
TABLE 111 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 114
TABLE 112 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 114
TABLE 113 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 114
TABLE 114 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 115
TABLE 115 ASIA PACIFIC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 115
9.4.1 CHINA 115
9.4.1.1 Increasing incidence of DFUs to propel the market growth 115
TABLE 116 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 116
TABLE 117 CHINA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 116
TABLE 118 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 116
TABLE 119 CHINA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 117
TABLE 120 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 117
TABLE 121 CHINA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 117
9.4.2 JAPAN 118
9.4.2.1 Growing geriatric population to drive the adoption of wound care products 118
TABLE 122 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 118
TABLE 123 JAPAN: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 119
TABLE 124 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 119
TABLE 125 JAPAN: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 119
TABLE 126 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 120
TABLE 127 JAPAN: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 120
9.4.3 INDIA 120
9.4.3.1 Growing medical tourism in the country to support the market growth for wound biologics 120
TABLE 128 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 121
TABLE 129 INDIA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 121
TABLE 130 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 121
TABLE 131 INDIA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 122
TABLE 132 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 122
TABLE 133 INDIA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 122
9.4.4 REST OF ASIA PACIFIC 122
TABLE 134 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 123
TABLE 135 ROAPAC WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 123
TABLE 136 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2017–2020 (USD MILLION) 124
TABLE 137 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE,
2021–2027 (USD MILLION) 124
TABLE 138 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 124
TABLE 139 ROAPAC: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 125
9.5 LATIN AMERICA 125
9.5.1 RISING PREVALENCE OF CHRONIC DISEASES TO SUPPORT THE MARKET GROWTH 125
TABLE 140 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2017–2020 (USD MILLION) 125
TABLE 141 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT,
2021–2027 (USD MILLION) 126
TABLE 142 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION) 126
TABLE 143 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION) 126
TABLE 144 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2017–2020 (USD MILLION) 127
TABLE 145 LATIN AMERICA: WOUND CARE BIOLOGICS MARKET, BY END USER,
2021–2027 (USD MILLION) 127
9.6 MIDDLE EAST & AFRICA 127
9.6.1 SIGNIFICANT GROWTH IN HEALTHCARE INFRASTRUCTURE TO DRIVE THE MARKET GROWTH FOR WOUND BIOLOGICS 127
TABLE 146 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2017–2020 (USD MILLION) 128
TABLE 147 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY PRODUCT, 2021–2027 (USD MILLION) 128
TABLE 148 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2017–2020 (USD MILLION) 128
TABLE 149 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY WOUND TYPE, 2021–2027 (USD MILLION) 129
TABLE 150 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2017–2020 (USD MILLION) 129
TABLE 151 MIDDLE EAST & AFRICA: WOUND CARE BIOLOGICS MARKET, BY END USER, 2021–2027 (USD MILLION) 129
10 COMPETITIVE LANDSCAPE 130
10.1 OVERVIEW 130
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 130
10.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN THE WOUND CARE BIOLOGICS MARKET 130
TABLE 152 OVERVIEW OF STRATEGIES DEPLOYED BY KEY WOUND CARE BIOLOGICS MANUFACTURING COMPANIES 130
10.3 MARKET SHARE ANALYSIS 132
10.3.1 WOUND CARE BIOLOGICS MARKET 132
FIGURE 21 WOUND CARE BIOLOGICS MARKET SHARE, BY KEY PLAYER (2021) 132
TABLE 153 WOUND CARE BIOLOGICS MARKET: DEGREE OF COMPETITION 132
10.4 COMPANY EVALUATION QUADRANT 133
10.4.1 LIST OF EVALUATED VENDORS 133
10.4.2 STARS 134
10.4.3 EMERGING LEADERS 134
10.4.4 PERVASIVE PLAYERS 134
10.4.5 PARTICIPANTS 134
FIGURE 22 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021 135
10.5 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2021) 135
10.5.1 PROGRESSIVE COMPANIES 135
10.5.2 STARTING BLOCKS 136
10.5.3 RESPONSIVE COMPANIES 136
10.5.4 DYNAMIC COMPANIES 136
FIGURE 23 WOUND CARE BIOLOGICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2021 136
10.6 COMPETITIVE SCENARIO 137
10.6.1 PRODUCT LAUNCHES & REGULATORY APPROVALS 137
TABLE 154 KEY PRODUCT LAUNCHES & REGULATORY APPROVALS 137
10.6.2 DEALS 137
TABLE 155 KEY DEALS 137
10.6.3 OTHER DEVELOPMENTS 138
TABLE 156 OTHER DEVELOPMENTS 138
11 COMPANY PROFILES 139
11.1 KEY PLAYERS 139
(Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats)*
11.1.1 SMITH & NEPHEW PLC 139
TABLE 157 SMITH & NEPHEW PLC: BUSINESS OVERVIEW 139
FIGURE 24 SMITH & NEPHEW PLC: COMPANY SNAPSHOT (2021) 140
11.1.2 ORGANOGENESIS INC. 143
TABLE 158 ORGANOGENESIS INC.: BUSINESS OVERVIEW 143
FIGURE 25 ORGANOGENESIS INC.: COMPANY SNAPSHOT (2021) 143
11.1.3 MIMEDX 146
TABLE 159 MIMEDX: BUSINESS OVERVIEW 146
FIGURE 26 MIMEDX: COMPANY SNAPSHOT (2021) 146
11.1.4 INTEGRA LIFESCIENCES 148
TABLE 160 INTEGRA LIFESCIENCES: BUSINESS OVERVIEW 148
FIGURE 27 INTEGRA LIFESCIENCES: COMPANY SNAPSHOT (2021) 149
11.1.5 STRYKER CORPORATION 151
TABLE 161 STRYKER CORPORATION: BUSINESS OVERVIEW 151
FIGURE 28 STRYKER CORPORATION: COMPANY SNAPSHOT (2021) 152
11.1.6 MÖLNLYCKE HEALTH CARE AB 154
TABLE 162 MÖLNLYCKE HEALTH CARE AB: BUSINESS OVERVIEW 154
FIGURE 29 MÖLNLYCKE HEALTH CARE AB: COMPANY SNAPSHOT (2021) 155
11.1.7 VERICEL CORPORATION 157
TABLE 163 VERICEL CORPORATION: BUSINESS OVERVIEW 157
FIGURE 30 VERICEL CORPORATION: COMPANY SNAPSHOT (2021) 157
11.1.8 ANIKA THERAPEUTICS, INC. 158
TABLE 164 ANIKA THERAPEUTICS, INC.: BUSINESS OVERVIEW 158
FIGURE 31 ANIKA THERAPEUTICS, INC.: COMPANY SNAPSHOT (2021) 159
11.1.9 BIOVENTUS LLC 160
TABLE 165 BIOVENTUS LLC: BUSINESS OVERVIEW 160
FIGURE 32 BIOVENTUS LLC: COMPANY SNAPSHOT (2021) 161
11.1.10 ABBVIE INC. 163
TABLE 166 ABBVIE INC.: BUSINESS OVERVIEW 163
FIGURE 33 ABBVIE INC.: COMPANY SNAPSHOT (2021) 163
11.1.11 KERECIS 165
TABLE 167 KERECIS: BUSINESS OVERVIEW 165
11.1.12 MARINE POLYMER TECHNOLOGIES, INC. 166
TABLE 168 MARINE POLYMER TECHNOLOGIES, INC.: BUSINESS OVERVIEW 166
11.2 OTHER PLAYERS 167
11.2.1 MERAKRIS THERAPEUTICS 167
TABLE 169 MERAKRIS THERAPEUTICS: COMPANY OVERVIEW 167
11.2.2 POLYMEDICS INNOVATIONS GMBH 167
TABLE 170 POLYMEDICS INNOVATIONS GMBH: COMPANY OVERVIEW 167
11.2.3 FIBROHEAL WOUNDCARE PVT. LTD. 168
TABLE 171 FIBROHEAL WOUNDCARE PVT. LTD.: COMPANY OVERVIEW 168
11.2.4 ANAMAY BIOTECH, INC. 168
TABLE 172 ANAMAY BIOTECH, INC.: COMPANY OVERVIEW 168
11.2.5 VIRCHOW BIOTECH PRIVATE LIMITED 169
TABLE 173 VIRCHOW BIOTECH PRIVATE LIMITED: COMPANY OVERVIEW 169
11.2.6 MEDLINE INDUSTRIES, LP 169
TABLE 174 MEDLINE INDUSTRIES, LP: COMPANY OVERVIEW 169
11.2.7 TIDES MEDICAL 170
TABLE 175 TIDES MEDICAL: COMPANY OVERVIEW 170
11.2.8 VISCUS BIOLOGICS LLC 170
TABLE 176 VISCUS BIOLOGICS LLC: COMPANY OVERVIEW 170
11.2.9 STABILITY BIOLOGICS 171
TABLE 177 STABILITY BIOLOGICS: COMPANY OVERVIEW 171
11.2.10 MTF BIOLOGICS 171
TABLE 178 MTF BIOLOGICS: COMPANY OVERVIEW 171
11.2.11 SKYE BIOLOGICS HOLDINGS, LLC 172
TABLE 179 SKYE BIOLOGICS HOLDINGS, LLC: COMPANY OVERVIEW 172
11.2.12 ALLOSOURCE 172
TABLE 180 ALLOSOURCE: COMPANY OVERVIEW 172
11.2.13 SURGILOGIX 173
TABLE 181 SURGILOGIX: COMPANY OVERVIEW 173
*Details on Business overview, Products offered, Recent developments, MnM view, Key Strengths/Right to win, Strategic choices made, and Weakness and competitive threats might not be captured in case of unlisted companies.
12 APPENDIX 174
12.1 DISCUSSION GUIDE 174
12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 177
12.3 AVAILABLE CUSTOMIZATIONS 179
12.4 RELATED REPORTS 179
12.5 AUTHOR DETAILS 180

ページTOPに戻る

Table of Contents

Summary

The global wound care biologics market is valued at an estimated USD 1.8billion in 2022 and is projected to reach USD 2.4billion by 2027, at a CAGR of 5.4% during the forecast period. Market growth is driven by factors such asthe growing incidence of burn injuries and the rising number of road accidents and associated traumatic wounds. However, the high cost of wound care biologic products and the risk associated with skin substitute failure are the major factors hampering the growth of this market.

“The biological skin substitutes segment accounted for the highest growth rate in thewound care biologicsmarket, by product, during the forecast period”
The wound care biologics market is segmented into biological skin substitutes and topical agents. The biological skin substitutes is expected to register the highest growth rate during the forecast period. Factors such as the increasing burden of surgical & traumatic woundsand the increase in burn injuries arecontributing to the growth of this segment.
“Hospitalssegment accounted for the highest CAGR”
Based on end users, the wound care biologics market is segmented into hospitals, ambulatory surgery centers, and burn care centers & wound clinics. Hospitals segment is expected to register the highest CAGR during the forecast period. Extended hospital stays or readmissions of patients with chronic conditions have increased the adoption of various wound care biologic products. The increasing incidence of hospital-acquired wounds is a key growth driver for this market segment. Also, the adoption of wound care biologic products is higher in hospitals, owing to their higher purchasing power, highly skilled healthcare professionals, and access to technologically developed surgical facilities.
“The Asia Pacific market is expected to grow at the highest CAGR during the forecast period”
The global wound care biologics market is segmented into five regions - North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is expected to witness the highest growth in the wound care biologics market during the forecast period. The high growth in this region can primarily be attributed to the increasing prevalence of diabetes, rising healthcare spending, growing per capita income, the expansion of private-sector hospitals to rural areas in various APAC countries, increasing medical tourism, and the presence of high-growth markets.The low labor costs and favorable regulatory environment in the region are also expected to propel market growth.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report:

• Smith & Nephew plc (UK)
• Organogenesis Inc. (US)
• MIMEDX (US)
• Integra LifeSciences (US)
• Stryker Corporation (US)
• Mölnlycke Health Care AB (Sweden)
• Vericel Corporation (US)
• Bioventus LLC (US)
• Anika Therapeutics, Inc. (US)
• AbbVie Inc. (US)
• Kerecis (Iceland)
• Marine Polymer Technologies, Inc. (US)
• Merakris Therapeutics (US)
• PolyMedics Innovations GmbH (Germany)
• FibrohealWoundcarePvt. Ltd. (India)
• Anamay Biotech, Inc. (India)
• Virchow Biotech Private Limited (India)
• Medline Industries, LP (US)
• Tides Medical (US)
• Viscus Biologics LLC (US)
• Stability Biologics (US)
• MTF Biologics (US)
• Skye Biologics Holdings, LLC (US)
• AlloSource (US)
• SurgiLogix (US)

Research Coverage:
This report provides a detailed picture of the global wound care biologics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, wound type, end user,and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall wound care biologics market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（生物学的製剤）の最新刊レポート

MarketsandMarkets社の生物学的製剤分野での最新刊レポート

本レポートと同じKEY WORD（wound care）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

創傷治療用生物製剤市場：製品別（生体皮膚代替物、外用剤）、創傷タイプ別（潰瘍［糖尿病性足、静脈、褥瘡］、手術創・外傷、熱傷）、エンドユーザー別（病院、ASC、熱傷センター）-2027年までの世界市場予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（生物学的製剤）の最新刊レポート

MarketsandMarkets社の生物学的製剤分野での最新刊レポート

本レポートと同じKEY WORD（wound care）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?